Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context
Abstract
Mitochondrial glutamate-oxaloacetate (GOT2) is part of the malate-aspartate shuttle (MAS), a mechanism by which cells transfer reducing equivalents from the cytosol to the mitochondria. GOT2 is a key component of mutant KRAS (KRAS*)-mediated rewiring of glutamine metabolism in pancreatic ductal adenocarcinoma (PDA). Here, we demonstrate that the loss of GOT2 disturbs redox homeostasis and halts proliferation of PDA cells in vitro. GOT2 knockdown (KD) in PDA cell lines in vitro induced NADH accumulation, decreased Asp and α-ketoglutarate (αKG) production, stalled glycolysis, disrupted the TCA cycle, and impaired proliferation. Oxidizing NADH through chemical or genetic means resolved the redox imbalance induced by GOT2 KD, permitting sustained proliferation. Despite a strong in vitro inhibitory phenotype, loss of GOT2 had no effect on tumor growth in xenograft PDA or autochthonous mouse models. We show that cancer-associated fibroblasts (CAFs), a major component of the pancreatic tumor microenvironment (TME), release the redox active metabolite pyruvate, and culturing GOT2 KD cells in CAF conditioned media (CM) rescued proliferation in vitro. Furthermore, blocking pyruvate import or pyruvate-to-lactate reduction prevented rescue of GOT2 KD in vitro by exogenous pyruvate or CAF CM. However, these interventions failed to sensitize xenografts to GOT2 KD in vivo, demonstrating the remarkable plasticity and differential metabolism deployed by PDA cells in vitro and in vivo. This emphasizes how the environmental context of distinct pre-clinical models impacts both cell-intrinsic metabolic rewiring and metabolic crosstalk with the tumor microenvironment (TME).
Data availability
All data generated or analyzed during this study are included in the manuscript and supporting Source Data file; raw data are provided for metabolomics experiments, separated by tabs, in Supplemental Table 1.
Article and author information
Author details
Funding
National Institute of Allergy and Infectious Diseases (T32AI007413)
- Samuel Kerk
National Cancer Institute (R37CA237421)
- Costas A Lyssiotis
National Cancer Institute (R01CA248160)
- Costas A Lyssiotis
National Cancer Institute (R01CA244931)
- Costas A Lyssiotis
National Cancer Institute (F31CA254079)
- Jennifer A Jiménez
National Institute of Diabetes and Digestive and Kidney Diseases (T32-DK094775)
- Barbara S Nelson
National Cancer Institute (T32-CA009676)
- Barbara S Nelson
National Cancer Institute (R50 CA232985)
- Yaqing Zhang
National Institute of General Medical Sciences (T32-GM11390)
- Samantha B Kemp
National Cancer Institute (F31-CA247076)
- Samantha B Kemp
National Cancer Institute (T32-CA009676)
- Nina G Steele
National Cancer Institute (F31CA24745701)
- Samuel Kerk
American Cancer Society (PF-19-096-01)
- Nina G Steele
National Cancer Institute (K99CA241357)
- Christopher J Halbrook
National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034933)
- Christopher J Halbrook
National Institute of General Medical Sciences (R01GM101171)
- David B Lombard
National Cancer Institute (CA253986)
- David B Lombard
National Cancer Center (P30 CA046592)
- Costas A Lyssiotis
National Cancer Institute (1F99CA264414-01)
- Samuel Kerk
National Cancer Institute (CA148828)
- Yatrik M Shah
National Cancer Institute (CA245546)
- Yatrik M Shah
Pancreatic Cancer Action Network (13-70-25-LYSS)
- Costas A Lyssiotis
V Foundation for Cancer Research (V2016-009)
- Costas A Lyssiotis
Sidney Kimmel Foundation (SKF-16-005)
- Costas A Lyssiotis
American Association for Cancer Research (17-20-01-LYSS)
- Costas A Lyssiotis
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: Animal experiments were conducted in accordance with the Office of Laboratory Animal Welfare and approved by the Institutional Animal Care and Use Committees of the University of Michigan. ULAM: PRO00008877
Reviewing Editor
- Lydia W S Finley, Memorial Sloan Kettering Cancer Center, United States
Publication history
- Preprint posted: August 7, 2020 (view preprint)
- Received: August 21, 2021
- Accepted: July 9, 2022
- Accepted Manuscript published: July 11, 2022 (version 1)
- Version of Record published: July 27, 2022 (version 2)
Copyright
© 2022, Kerk et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,457
- Page views
-
- 660
- Downloads
-
- 16
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Biochemistry and Chemical Biology
The glucagon-like peptide-1 receptor (GLP1R) is a broadly expressed target of peptide hormones with essential roles in energy and glucose homeostasis, as well as of the blockbuster weight-loss drugs semaglutide and liraglutide. Despite its large clinical relevance, tools to investigate the precise activation dynamics of this receptor with high spatiotemporal resolution are limited. Here, we introduce a novel genetically encoded sensor based on the engineering of a circularly permuted green fluorescent protein into the human GLP1R, named GLPLight1. We demonstrate that fluorescence signal from GLPLight1 accurately reports the expected receptor conformational activation in response to pharmacological ligands with high sensitivity (max ΔF/F0=528%) and temporal resolution (τON = 4.7 s). We further demonstrated that GLPLight1 shows comparable responses to glucagon-like peptide-1 (GLP-1) derivatives as observed for the native receptor. Using GLPLight1, we established an all-optical assay to characterize a novel photocaged GLP-1 derivative (photo-GLP1) and to demonstrate optical control of GLP1R activation. Thus, the new all-optical toolkit introduced here enhances our ability to study GLP1R activation with high spatiotemporal resolution.
-
- Biochemistry and Chemical Biology
- Immunology and Inflammation
Genes associated with increased susceptibility to multiple sclerosis (MS) have been identified, but their functions are incompletely understood. One of these genes codes for the RNA helicase DExD/H-Box Polypeptide 39B (DDX39B), which shows genetic and functional epistasis with interleukin-7 receptor-α gene (IL7R) in MS-risk. Based on evolutionary and functional arguments, we postulated that DDX39B enhances immune tolerance thereby decreasing MS risk. Consistent with such a role we show that DDX39B controls the expression of many MS susceptibility genes and important immune-related genes. Among these we identified Forkhead Box P3 (FOXP3), which codes for the master transcriptional factor in CD4+/CD25+ T regulatory cells. DDX39B knockdown led to loss of immune-regulatory and gain of immune-effector expression signatures. Splicing of FOXP3 introns, which belong to a previously unrecognized type of introns with C-rich polypyrimidine tracts, was exquisitely sensitive to DDX39B levels. Given the importance of FOXP3 in autoimmunity, this work cements DDX39B as an important guardian of immune tolerance.